ALUME BIOSCIENCES, INC.

Alume Biosciences is a clinical-stage biotechnology company based in San Diego, California, developing bevonescein (ALM-488), a first-in-class fluorescent nerve visualization drug designed to illuminate peripheral nerves in real time during surgery. Founded by surgeon-scientist Quyen Nguyen, MD/PhD at UC San Diego, the company's technology aims to reduce iatrogenic nerve damage in procedures such as head-and-neck and thyroid surgeries. Alume's Phase 3 pivotal trials met primary endpoints for nerve conspicuity and safety, positioning the company to pursue NDA submission with the US FDA in the second half of 2026.